Anti-inflammatory Effect of JBP 485 on Dextran Sulfate Sodium-induced Colitis in Mice

JBP485 (cyclo-trans-4-L-hydroxyprolyl-L-serine), a dipeptide first isolated from Laennec that is a proprietary product made from the hydrolysate of human placenta, has been reported to have several biological properties, such as anti-hepatotoxic, anti-inflammatory and anti-apoptotic activities. However, the effect of JBP485 on inflammatory bowel disease has not yet been reported. Here we investigated the effects of simultaneous and subsequent administration of JBP485 on dextran sulfate sodium (DSS)-induced colitis in mice. In both experimental protocols, DSS-induced colitis was established by giving mice drinking water containing 2% (w/v) DSS for 5 days. JBP485 (25 mg/kg) was orally administered once a day during and after DSS treatment for 5 days in the simultaneous administration experiment while after DSS treatment for 5 days in the subsequent administration experiment. In the simultaneous administration experiment, JBP485 did not improve disease progression, such as weight loss, diarrhea and visible fecal blood, as well as shortening of the colon, but reduced the DSS-induced injury and up-regulation of tumor necrosis factor-α, interleukin-1β, cyclooxygenase-2, monocyte chemotactic protein 1 and C-X-C motif chemokine ligand 1 mRNAs in the colon. In the subsequent administration experiment, however, JBP485 did not show any effects on DSS-induced colitis. These results demonstrated that simultaneous administration but not subsequent administration of JBP485 had anti-inflammatory effects on DSS-induced colitis in mice.